Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Iovance Biotherapeutics (IOVA) over the last 11 years, with Q3 2025 value amounting to -$18.1 million.

  • Iovance Biotherapeutics' Other Working Capital Changes fell 56052.44% to -$18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.7 million, marking a year-over-year decrease of 455.89%. This contributed to the annual value of -$12.1 million for FY2024, which is 1185.84% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Other Working Capital Changes of -$18.1 million as of Q3 2025, which was down 56052.44% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Other Working Capital Changes registered a high of $6.9 million during Q2 2025, and its lowest value of -$18.1 million during Q3 2025.
  • Moreover, its 3-year median value for Other Working Capital Changes was -$2.7 million (2023), whereas its average is -$2.8 million.
  • Data for Iovance Biotherapeutics' Other Working Capital Changes shows a peak YoY increase of 316398.1% (in 2025) and a maximum YoY decrease of 56052.44% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Other Working Capital Changes stood at -$2.7 million in 2023, then crashed by 34.23% to -$3.7 million in 2024, then tumbled by 396.8% to -$18.1 million in 2025.
  • Its Other Working Capital Changes was -$18.1 million in Q3 2025, compared to $6.9 million in Q2 2025 and $3.3 million in Q1 2025.